Gastrointestinal Microflora: Probiotics

Advances in Applied Microbiology

Volumn 59, Issue , 2006, Pages 187-219

  Kolida, S ^a   Saulnier, D M ^a   Gibson, G R ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIMEL; ACTIVIA; AGELADITSA PLUS; ANTIBIOTIC AGENT; BIOPOT; CASERIO BIO; CULTURA; ENJOY; GEFILUS; LC1; LIFE TOP; MESALAZINE; O'SOY; PROBIOTIC AGENT; PROVIVA; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; VIFIT VITAMEL; VITA FRESH; VITALLITY; YAKULT; YOGACTIVE; YOGHURT;

ALLERGIC RHINITIS; ASTHMA; ATOPY; BACTERIUM CULTURE; BIFIDOBACTERIUM; CLINICAL TRIAL; DAIRY PRODUCT; DIARRHEA; DIGESTION; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FERMENTED PRODUCT; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL IRRITATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ILEITIS; IMMUNE SYSTEM; INFECTIOUS DIARRHEA; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS FERMENTUM; LACTOBACILLUS RHAMNOSUS; LACTOSE INTOLERANCE; MICROFLORA; MICROORGANISM; MILK; MILK ALLERGY; NAUSEA; PROPIONIBACTERIUM; REVIEW; SACCHAROMYCES; SACCHAROMYCES BOULARDII; STREPTOCOCCUS; TASTE DISORDER; TRAVELLER DIARRHEA; ULCERATIVE COLITIS; UROGENITAL TRACT INFECTION;

ANIMALS; BIFIDOBACTERIUM; DIARRHEA; FOOD MICROBIOLOGY; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS; PROBIOTICS;

EID: 33745620714     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2164(06)59007-0     Document Type: Review

References (135)

1. Allen S.J., Okoko B., Martinez E., Gregorio G., and Dans L.F. Probiotics for treating infectious diarrhoea. Cochrane Database Syst. Rev. 2 (2004) CD003048
2. Antonio M.A., Hawes S.E., and Hillier S.L. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J. Infect. Dis. 180 (1999) 1950-1956
3. Armuzzi A., Cremonini F., Bartolozzi F., Canducci F., Candelli M., Ojetti V., Cammarota G., Anti M., De Lorenzo A., Pola P., Gasbarrini G., and Gasbarrini A. The effect of oral administration of Lactobacillis GG on antibiotic associated gastrointestinal side effects during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 15 (2001) 163-169
4. Arvola T., Laiho K., Torkkeli S., Mykkanen H., Salminen S., Maunula L., and Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study. Pediatrics 104, (1999) art. no.-e64.
5. Asghar R.J., and Parsonnet J. Helicobacter pylori and risk for gastric adenocarcinoma. Semin. Gastrointest. Dis. 12 3 (2001) 203-208
6. Balsari A., Ceccarelli A., Dubini F., Fesce E., and Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 5 (1982) 185-194
7. Beerens H., Romond C., and Neut C. Influence of breast feeding on the bifidus flora of the newborn intestine. Am. J. Clin. Nutr. 33 (1980) 2434-2439
8. Bibiloni R., Fedorak R.N., Tannock G.W., Madsen K.L., Gionchetti P., Campieri M., De simone C., and Sartor R.B. VSL3# probiotic mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100 (2005) 1-8
9. Boddy A.V., Elmer G.W., McFarland L.V., and Levy R.H. Influence of antibiotics on the recovery and kinetics of Saccharomyces-boulardii in rats. Pharm. Res. 8 (1991) 796-800
10. Bradley H.K., Wyatt G.M., Bayliss C.E., and Hunter J.O. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J. Med. Microbiol. 23 (1987) 29-32
11. Brigidi P., Vitali B., Swennen E., Bazzocchi G., and Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhoea. Res. Microbiol. 152 (2001) 735-741
12. Burton J.P., Cadieux P., and Reid G. Improved understanding of the bacterial vaginal microflora of women before and after probiotic instillation. Appl. Environ. Microbiol. 69 (2003) 97-101
13. Casburn-Jones A.C., and Farthing M.J. Management of infectious diarrhoea. Gut 53 2 (2004) 296-305
14. Chan R.C.Y., Bruce A.W., and Reid G. Adherence of cervical, vaginal and distal urethral normal microbial flora to human uroepithelial cells and the inhibition of adherence of uropathogens by competitive exclusion. J. Urol. 131 (1984) 596-601
15. Chiba C., Nakamura T., Hoshina S., and Kitagawa Y. Optimal cases and sites to search for primary microbial agents in Crohn's disease. Gastroenterology 120 (2001) 1066-1067
16. Clabots C.R., Johnson S., Olson M.M., Peterson L.R., and Gerding D.N. Acquisition of Clostridium difficile by hospitalized patients: Evidence for colonized new admissions as a source of infection. J. Infect. Dis. 166 (1992) 561-567
17. Cremonini F., and Talley N.J. Irritable bowel syndrome: Epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol. Clin. North Am. 34 2 (2005) 189-204
18. Crittenden R.G., and Playne M.J. Production, properties and applications of food-grade oligosaccharides. Trends Food Sci. Technol. 7 (1996) 353-360
19. Darfuille-Michaud A., Neut C., Barnich N., Lederman E., Di Martino P., Desreumaux P., Gambiez L., Joly B., Cortot A., and Colombel J.F. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115 (1998) 1405-1413
20. Dunne C., O'Mahony L., Murphy L., Thornton G., Morrissey D., O'Halloran S., Feeney M., Flynn S., Fitgerald G., Daly C., Kiely B., O'Sullivan G.C., et al. In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings. Am. J. Clin. Nutr. 73 suppl (2001) 386S-392S
21. El-Zaatari F.A., Naser S.A., Hulten K., Burch P., and Graham D.Y. Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease in humans. Curr. Microbiol. 39 (1999) 115-119
22. Fabia R., Ar'rajab A., Johansson ML., Willén R., and Andersson R. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand. J. Gastroenterol. 28 (1993) 155-162
23. FAO/WHO. Working group report on drafting guidelines for the evaluation of probiotics in food (2002), Ontario, London
24. Finegold S.M., Sutter V.L., and Mathisen G.E. In: Hentges D.J. (Ed). "Human Intestinal Microflora in Health and Disease" (1983), Academic Press, London
25. Florin T.H.J., Gibson G.R., and Neale G. A role for sulphate reducing bacteria in ulcerative colitis?. Gastroenterology 98 5 (1990) A170
26. Fox J.G., Gorelick P.L., Kullberg M.C., Zhongming G., Dewhirst F.E., and Ward J.M. A novel urease-negative Helicobacter species associated with colitis and typhitis in IL-10-deficient mice. Infect. Immun. 64 (1999) 1757-1762
27. Fukushima Y., Kawata Y., Mizumachi K., Kurisaki J., and Mitsuoka T. Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Int. J. Food Microbiol. 46 (1999) 193-197
28. Fuller R. Probiotics in human medicine. Gut 32 (1991) 432-442
29. Gibson G.R., and Roberfroid M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 125 (1995) 1401
30. Gibson G.R., Cummings J.H., and Macfarlane G.T. Growth and activities of sulphate reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 103 (1991) 103-112
31. Gibson G.R., Wynne A., and Bird A. In: Sadler M., Caballero B., and Strain S. (Eds). "Encyclopedia of Human Nutrition" (1998), Academic Press, London 1282-1289
32. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzochi G., Poggioli G., Miglioli M., and Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
33. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., Vitali B., Poggioli G., Miglioli M., and Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 124 5 (2003) 1202-1209
34. Guarner F., Perdigon G., Corthier G., Salminen S., Koletzko B., and Morelli L. Should yogourt culture considered as probiotics?. Br. J. Nutr. 93 (2005) 783-786
35. Guslandi M., Giollo P., and Testoni P.A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 15 (2003) 697-698
36. Hamilton-Miller J.M.T., Shah S., and Winkler J.T. Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr. 2 (1999) 223-229
37. Harmsen H.J.M., Raangs G.C., He T., Degener J.E., and Wellin G.W. Extensive set of 16S rRNA-based probes for detection of bacteria in human feces. Appl. Environ. Microbiol. 68 (2002) 2982-2990
38. Hattori K., Yamamoto A., Sasai M., Taniuchi S., Kojima T., Kobayashi Y., Iwamoto H., Namba K., and Yaeshima T. Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. Arerugi 52 (2003) 20-30
39. Havenaar R., and Huis In't Veld M.J.H. "Lactic Acid Bacteria in Health and Disease: Probiotics a General View," Vol. 1 (1992), Elsevier Applied Science Publishers, Amsterdam
40. Helin T., Haahtela S., and Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: A placebo-controlled double-blind study. Allergy 57 (2002) 243-246
41. Hermon-Taylor J., Bull T.J., Sheridan J.M., Cheng J., Stellakis M.L., and Sumar N. Causation of Crohn's disease by Mycobacterium avium subspecies paratuberculosis. Can. J. Gastroenterol. 14 (2000) 162-163
42. Hessle C., Hanson L.A., and Wold A.E. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin. Exp. Immunol. 116 (1999) 276-282
43. Hilton E., Kolakowski P., Singer C., and Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travellers. J. Travel Med. 1 (1997) 41-43
44. Holma R., Salmenperä P., Lohi J., Vapaatalo H., and Korpela R. Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on acetic acid-induced colitis in rats. Scan J. Gastroenterol. 36 (2001) 630-635
45. Ishikawa H., Akedo I., Umesaki Y., Tanaka R., Imaoka A., and Otani T. Randomized controlled trial of the effect of Bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr. 22 (2003) 56-63
46. Isolauri E., Juntunen M., Rautanen T., Sillanaukee P., and Koivula T. A human Lactobacillus strain (Lactobacillus-Casei Sp Strain Gg) promotes recovery from acute diarrhea in children. Pediatrics 88 (1991) 90-97
47. Isolauri E., Arvola T., Sutas Y., Moilanen E., and Salminen S. Probiotics in the management of atopic eczema. Clin. Exp. Allergy 30 (2000) 1604-1610
48. Kaila M., Isolauri E., Soppi E., Virtanen E., Laine S., and Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human lactobacillus strain. Pediatr. Res. 32 (1992) 141-144
49. Kaila M., Isolauri E., Saxelin M., Arvilommi H., and Vesikari T. Viable versus inactivated lactobacillus strain Gg in acute rotavirus diarrhea. Arch. Dis. Child. 72 (1995) 51-53
50. Kalliomaki M., Salminen S., Arvilommi H., Kero P., Koskinen P., and Isolauri E. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. Lancet 357 (2001) 1076-1079
51. Kalliomaki M., Salminen S., Poussa T., Arvilommi H., and Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 361 (2003) 1869-1871
52. Katelaris P.H., Salam I., and Farthing M.J.G. Lactobacilli to prevent travelers diarrhea. N. Engl. J. Med. 333 (1995) 1360-1361
53. Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., and Zinsmeister A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 17 (2003) 895-904
54. Kirjavainen P.V., Salminen S.J., and Isolauri E. Probiotic bacteria in the management of atopic disease: Underscoring the importance of viability. J. Pediatr. Gastroenterol. Nutr. 36 2 (2003) 223-227
55. Kollaritsch von H., Holst H., Grobara P., and Wiedermann G. Prophylaxe des Reisediarrhöe mit Saccharomyces boulardii. (Prevention of travelers' diarrhea by Saccharomyces boulardii. Results of a placebo-controlled double-blind study). Fortschr. Med. 111 (1993) 153-156
56. Kotowska M., Albrecht P., and Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 21 (2005) 583-590
57. Kruis W., Schuts E., Fric P., Fixa B., Judmaier G., and Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11 (1997) 853-858
58. Kruis W., Pokrotnieks J., Lukas M., Fixa B., Kascak M., Kamm M.A., Weismueller J., Berlinger C., Stolte M., Wolff C., and Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escerichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 11 (2004) 1617-1623
59. Kuisma J., Mentula S., Jarvinen H., Jarvinen H., Kahri A., and Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment. Pharmacol. Ther. 17 (2003) 509-516
60. Kullberg M.C., Ward J.M., Gorelick P., Caspar P., Hieny S., Cheever A., Jankovic D., and Sher A. Helicobacter hepaticus triggers colitis in specific pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12 and gamma interferon-dependent mechanism. Infect. Immun. 66 (1998) 5157-5166
61. Lee S.Y., Chang C.T., Lee M.H., and Wu M.S. Lactobacillus peritonitis: A rare cause of peritonitis in peritoneal dialysis patients. Ren. Fail. 26 (2004) 419-424
62. Levine J., Ellis C.J., Furne J.K., Springfield J.R., and Levitt M.D. Sulphate reducing bacteria and ulcerative colitis. Immunol., Microbiol. and Inflamm. Disord. A949 (1996)
63. Levri K.M., Ketvertis K., Deramo M., Merenstein J.H., and D'Amico F. Do probiotics reduce adult lactose intolerance? A systematic review. J. Fam. Pract. 54 (2005) 613-620
64. Lewis S.J., Potts L.F., and Barry R.E. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J. Infect. 36 (1998) 171-174
65. Lilly D.M., and Stillwell R.H. Probiotics: Growth promoting factors produced by microorganisms. Science 147 (1965) 747-748
66. Mackay A.D., Taylor M.B., Kibbler C.C., and Hamilton-Miller J.M. Lactobacillus endocarditis caused by a probiotic organism. Clin. Microbiol. Infect. 5 (1999) 290-291
67. Macpherson A., Khoo U.Y., Forgacs I., Philpott-Howard J., and Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38 (1996) 365-375
68. Madden J.A.J., Plummer S., Sen S., Dear K., Tarry S., and Hunter J.O. Comparison of the cecal and faecal microflora of healthy subjects and patients with irritable bowel syndrome. Gut 48 suppl. 1 (2001) A58
69. Madsen K.L., Doyle J.S., Tavernini M.M., and Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116 (1999) 1107-1114
70. Majamaa H., and Isolauri E. Probiotics: A novel approach in the management of food allergy. J. Allergy Clin. Immunol. 99 (1997) 179-185
71. Majamaa H., Isolauri E., Saxelin M., and Vesikari T. Lactic-acid bacteria in the treatment of acute rotavirus Gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 20 (1995) 333-338
72. Mao Y., Nobaek S., Kasravi B., Adawi D., Stenram U., Molin G., and Jeppsson B. The effects of Lactobacillus strains and oat fibre on methotrexate-induced enterocolitis in rats. Gastroenterology 111 (1996) 334-344
73. Marteau P., Flourie B., Pochart P., Chastang C., Desjeux J.F., and Rambaud J.C. Effect of the microbial lactase (Ec 3.2.1.23) activity in yogurt on the intestinal-absorption of lactose-an in vivo study in lactase-deficient humans. Br. J. Nutr. 64 (1990) 71-79
74. Marteau P., Vesa T., and Rambaud J.C. Lactose maldigestion. In: Fuller R. (Ed). "Probiotics" (1997), Chapman & Hall, London 65-88
75. Maybery J.F., Probert C.S.J., Jayanthi V., and Shivananda S. In: Anagnostides A.A., Hodgson H.J.F., and Kirsner J.B. (Eds). "Inflammatory Bowel Disease" (1991), Chapman and Hall, London 163
76. McFarland L.V. A randomized placebo-controlled trial of Saccharomyces-boulardii in combination with standard antibodies for clostridium-difficile-disease. JAMA 271 (1994) 1913-1918 [Published erratum appears in JAMA 272, 518].
77. McGroarty J.A., Tomeczek L., Pond D.G., Reid G., and Bruce A.Wl. Hydrogen peroxide production by lactobacillus species, correlation with susceptibility to the spermicidal compound nonoxynol-9. J. Infect. Dis. 165 6 (1992) 1142-1144
78. Metchnikoff E. "The Prolongation of Life." (1907), William Heinemann, London
79. Miettinen M., Matikainen S., Vuopio-Varkila J., Pirhonen J., Varkila K., Kurimoto M., and Julkunen I. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect. Immun. 66 (1998) 6058-6062
80. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., Nicholls R.J., Gionchetti P., Campieri M., and Kamm M.A. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
81. Mitsuoka T. Intestinal flora and aging. Nutr. Rev. 50 (1992) 438-446
82. Moore W.E., and Holdeman L.V. Human faecal flora: The normal flora of 20 Japanese-Hawaians. Appl. Environ. Microbiol. 27 (1974) 961-979
83. Myllyluoma E., Veijola L., Ahlroos T., Tynkkynen S., Kankuri E., Vapaatalo H., Rautelin H., and Korpela R. Probiotic supplementation improves tolerance to helicobacter pylori eradication therapy-a placebo controlled, double-blind randomized pilot study. Aliment. Pharmacol. Ther. 21 (2005) 1263-1272
84. Niedzielin K., Kordecki H., and Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. J. Gastroenterol. Hepatol. 13 (2001) 1143-1148
85. Nissle A. Weiteres uber Grundlagen und Praxis der Mutaflorbehandlung. Dtsch. Med. Wochenschr. 44 (1925) 1809-1813
86. Nobaeck S., Johansson M.L., Molin G., Ahrne S., and Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 95 (2000) 1231-1238
87. O'Sullivan M., and O'Morain C. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig. Liver Dis. 32 (2000) 294-301
88. Oksanen P.J., Salminen S., Saxelin M., Hamalainen P., Ihantola-Vormisto A., Muurasniemi-Isoviita L., Nikkari S., Oksanen T., Porsti I., and Salminen E. Prevention of travelers diarrhea by lactobacillus GG. Ann. Med. 22 (1990) 53-56
89. Paganelli R., Ciuffreda S., Verna N., Cavallucci E., Paolini F., Ramondo S., and Di Gioacchino M. Probiotics and food-allergic diseases. Allergy 57 (2002) 97-99
90. Parker R.B. Probiotics, the other half of the antibiotic story. Anim. Nutr. Health 29 (1974) 4-8
91. Pathmakanthan S., Thornley J.P., and Hawkey C.J. Mucosally associated bacterial flora of the human colon: Quantitative and species specific differences between normal and inflamed colonic biopsies. Microb. Ecol. Health Dis. 11 (1999) 169-174
92. Pelto L., Isolauri E., Lilius E.M., Nuutila J., and Salminen S. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin. Exp. Allergy 28 (1998) 1474-1479
93. Pessi T., Sütas Y., Saxelin M., Kallioinen H., and Isolauri E. Antiproloferarive effects of homogenates derived from five strains of candidate probiotic bacteria. Appl. Environ. Microbiol. 65 11 (1999) 4725-4728
94. Pitcher M.C.L., Beatty E.R., and Cummings J.H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46 (2000) 64-72
95. Pozoolano J.D.D., Warram J.H., Gomez R.G., and Cavazos M.G. Effect of a Lactobacilli preparation on travelers diarrhea-randomized, double-blind clinical-trial. Gastroenterology 74 (1978) 829-830
96. Rautio M., Jousimies-Somer H., Kauma H., Pietatinen I., Saxelin M., Tykkynen S., and Koskela M. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus Strain GG. Clin. Infect. Dis. 28 (1999) 1159
97. Reid G., and Bruce A.W. Low vaginal pH and urinary tract infection. Lancet 346 (1995) 1704
98. Reid G., and Bruce A.W. Urogenital infections in women: Can probiotics help?. Postgrad. Med. J. 79 (2003) 428-432
99. Reid G., Cook R.L., and Bruce A.W. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J. Urol. 138 (1987) 330-335
100. Reid G., Bruce A.W., and Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol. Ther. 23 (1995) 32-45
101. Rembacken B.J. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis. Lancet 354 (1999) 635-639
102. Rochet V., Rigottier-Gois L., Beguet F., and Dore J. Composition of human intestinal flora analysed by fluorescent in situ hybridisation using group-specific 16S rRNA-targeted oligonucleotide probes. Genet. Sel. Evol. 33 (2001) S339-S352
103. Rosenfeldt V., Benfeldt E., Nielsen S.D., Mickaelsen K.F., Jeppesen D.L., and Valerius N.H. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 111 (2003) 389-395
104. Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., and Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 47 (2001) 709-710
105. Salminen S. Uniqueness of probiotic strains, IDF. Nutr. News Lett. 5 (1996) 16-18
106. Sanders M.E., Tompkins T., Heimbach J.T., and Kolida S. Weight of evidence needed to substantiate a health effect for probiotics and prebiotics. Regulatory considerations in Canada, EU and U.S. Eur. J. Nutr. 44 5 (2004) 303-310
107. Sartor R.B. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res. Immunol. 148 (1997) 567-575
108. Schmidt V., Wolter M., Lenschow U., and Kienast W. Lactobacillus paracasei-endocarditis in an case of 18 year old female patient with trisomie 21, atrioventricular septal defect and Eisenmenger's complex-therapeutic problems. Klin. Padiatr. 213 (2001) 35-38
109. Sen S., Mullan M.M., Parker T.J., Woolner J.T., Tarry S.A., and Hunter J.O. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci. 47 (2002) 2615-2620
110. Sghir A., Dore J., and Mackie R.I. Molecular ecology in gastrointestinal systems. Proceedings of the 8th Symposium on Microbial Ecology (1999)
111. Sghir A., Gramet G., Suau A., Rochet V., Pochart P., and Dore J. Quantification of bacterial groups within human faecal flora by oligonucleotide probe hybridisation. Appl. Environ. Microbiol. 66 (2000) 2263-2266
112. Sheu B.S., Wu J.J., Lo C.Y., Wu H.W., Chen J.H., Lin Y.S., and Lin M.D. Impact of supplement with lactobacillus and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 16 (2002) 1669-1675
113. Stark P.L., and Lee A. The microbial ecology of the large bowel of the breast-fed infants during the first year of life. J. Med. Microbiol. 15 (1982) 189-203
114. Suau A., Bonnet R., Sutren M., Godon J.J., Gibson G.R., Collins M.D., and Dore J. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl. Environ. Microbiol. 65 (1999) 4799-4807
115. Surawicz C.M., Elmer G.W., Speelman P., McFarland L.V., Chinn J., and Vanbelle G. Prevention of antibiotic-associated diarrhea by Saccharomyces-boulardii-a prospective-study. Gastroenterology 96 (1989) 981-988
116. Sykora J., Valeckova K., Amlerova J., Siala K., Dadek P., Watkins S., Varvarovska J., Stozicky F., Pazdiora P., and Schwartz J. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: A prospective randomized double-blind study. J. Clin. Gastroenterol. 39 8 (2005) 692-698
117. Szajewska H., Kotowska M., Mrukowicz J.Z., Armanska M., and Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr. 138 (2001) 361-365
118. Szilagyi A. Redefining lactose as a conditional prebiotic. Can. J. Gastroenterol. 18 (2004) 163-167
119. Tannock G.W. Studies on the intestinal microflora: A prerequisite for the development of probiotics. Int. Dairy Journal 8 (1998) 527-533
120. Tannock G.W. Molecular assessment of intestinal microflora. Am. J. Clin. Nutr. 73 (2001) 410S-414S
121. Temmerman R., Pot B., Huys G., and Swings J. A quality analysis of commercial probiotic products. Mededelingen-Faculteit Landbouwkundige En Toegepaste Biologische Wetenschappen 66 (2001) 535-542
122. Thomas M.R., Litin S.C., Osmon D.R., Corr A.P., Weaver A.L., and Lohse C.M. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: A randomized, placebo-controlled trial. Mayo Clin. Proc. 76 (2001) 883-889
123. Vanderhoof J.A., Whitney D.B., Antonson D.L., Hanner T.L., Lupo J.V., and Young R.J. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J. Pediatr. 135 (1999) 564-568
124. Velraeds M.M., van der Mei H.C., Reid G., and Busscher H.J. Inhibition of initial adhesion or uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl. Environ. Miocrobiol. 62 (1996) 1958-1963
125. Veltkamp C., Tonkonogy S.L., De Jong Y.P., Albright C., Grenther W.B., Balish E., Terhorst C., and Sartor R.B. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tgepsilon26 Mice. Gastroenterology 120 (2001) 900-913
126. Venturi A., Gionchetti P., Rizzelo F., Johansson R., Zucconi E., Bridigi P., Matteuzzi D., and Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13 (1999) 1103-1108
127. Vergin F. Anti-und Probiotika. Hippokrates 25 (1954) 116-119
128. Viljanen M., Savilahti E., Haahtela T., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., and Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: A double-blind placebo-controlled trial. Allergy 60 (2005) 494-500
129. Wang K.Y., Liu C.S., Perng D.S., Su Y.C., Wu D.C., Jan C.M., Wang T.N., and Wang W.M. Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am. J. Clin. Nutr. 80 3 (2004) 737-741
130. Weese J.S. Evaluation of deficiencies in labelling of commercial probiotics. Can. Vet. J. 44 (2003) 982-983
131. Wendakoon C.N., Thomson A.B., and Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion 65 1 (2002) 16-20
132. Weston S., Halbert A., and Prescott S.L. Effects of probiotics on atopic dermatitis: A randomised controlled trial. Arch. Dis. Child. 90 9 (2005) 892-897
133. WHO. The world health report: Shaping the future (2003) 3-22
134. Yates J. Traveler's diarrhea. Am. Fam. Physician 71 (2005) 2095-2100
135. Yesovitch R., Cohen A., and Szilagyi A. Failure to improve parameters of lactose maldigestion using the multiprobiotic product VSL3 in lactose maldigesters: A pilot study. Can. J. Gastroenterol. 18 (2004) 83-86